Fighting back against chikungunya (Q40166831)

18 September 2017

title

Fighting back against chikungunya (English)

1 reference

18 September 2017

0 references

Suresh Mahalingam

1 reference

18 September 2017

Penny A Rudd

1 reference

18 September 2017

publication date

2 March 2015

1 reference

Lancet Infectious Diseases

18 September 2017

published in

1 reference

18 September 2017

1 reference

18 September 2017

1 reference

18 September 2017

page(s)

488-489

1 reference

Chikungunya: a re-emerging virus

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

A single mutation in chikungunya virus affects vector specificity and epidemic potential

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

Chikungunya on the move

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

US Military contributions to the global response to pandemic chikungunya

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

Prime-boost immunization strategies against Chikungunya virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2970079-4

7 January 2021

Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25739877

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1016/S1473-3099(15)70079-4

1 reference

18 September 2017

1 reference